- Litigation / Dispute Resolution (17)
- Intellectual Property (16)
- Healthcare (14)
- Information Technology (7)
- Regulatory and compliance (7)
- Employment (6)
- Clinical/Medical Negligence (5)
- Company/Commercial (5)
- Commodities (3)
- Competition/EU (3)
- Corporate (3)
- Media/Entertainment/Sport (3)
- Banking / Finance (2)
- Energy (2)
- Environment (2)
- Privacy and reputation (2)
- Tax (2)
- Crime (1)
- Financial services (1)
- Funds (1)
- Insurance/reinsurance (1)
- Pensions (1)
- Personal tax / Trusts (1)
- Planning (1)
- Real Estate (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
Patents directed to genetic material have been the subject of significant public discourse and legal challenge worldwide.
The Supreme Court ruled in FTC v Actavis that settlement agreements for patent infringement suits between branded and generic drug companies are not immune from antitrust scrutiny.
Health Alert — Gray v Richards; Psychology Board of Australia v G; health insurance legislation amendment; and more
DLA Piper has released the 20 October 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
This guide provides sound, practical advice on the relevant laws and regulations for foreign companies looking to invest in Australia.
In D’Arcy v Myriad Genetics, five judges of the Full Federal Court of Australia have confirmed that isolated nucleic acid sequences are patentable subject matter in Australia.
Debates on the laws and regulations that will govern biosimilar products have been raging for some time.
Intellectual Property and Technology News — state biosimilars laws are evolving; surviving a trademark opposition challenge; and more
DLA Piper has released issue 23 of its Intellectual Property and Technology News, which reports on worldwide developments in IP and technology law.
Life Sciences Spotlight: Chinese regulatory enforcement action not slowing down; patent strategies and loyalty discounts; and more
DLA Piper has released the fourth edition of Life Sciences Spotlight, which discusses developments in the sector across the Asia-Pacific region.
Life Sciences Spotlight: Chinese regulatory enforcement action showing no signs of slowing down; and more
Welcome to the fourth edition of Life Sciences Spotlight.
European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m on the French pharmaceutical company Servier and five producers of generic medicines.
Antitrust and competition enforcement is changing fast: our report for multinationals from three global conferences
The world of antitrust/competition enforcement is changing more rapidly than ever. This evolving environment presents new challenges for companies.
In food marketing litigation, class certification is a major hurdle for would-be class plaintiffs, but a recent case may have lowered the bar with a flexible approach to class certification.
California GCI’s coming priority products list and the DTSC Strategic Plan — what do they mean for you?
The highly anticipated next step in California’s Green Chemistry Initiative (GCI) is the planned April 2014 release of the list of ‘priority products’.
DLA Piper has released the 3 February 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has released the 28 January 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The Australian High Court has delivered its first judgment that directly considers the patentability of methods of medical treatment.
A recent decision by the Court of Appeal provides useful guidance on the correct approach to defining the market in relation to pharmaceutical products.
Despite 20 states allowing the use of medicinal marijuana and two more allowing recreational marijuana use, employers remain unaffected.